As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > COMMENTARY
COMMENTARY
-
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
-
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
-
Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
-
Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
-
Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
-
GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
-
Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
-
Japan's Most Admired Pharma Companies in 2010
April 4, 2011
-
Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
-
Use of Generics by Welfare Recipients
March 7, 2011
-
Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
-
Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
-
Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
-
Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
-
How to Eliminate Concerns about Safety of Liovel
October 4, 2010
-
Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…